Celcuity, Inc. (CELC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$69.24-0.69%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
Research Workspace
Put CELC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Improve earnings to positive by FY 2027: Comparison needs review.
View ThesisRanks in the weakest quality tier of its industry — roughly the bottom 46%, softest on share dilution.
View QualityThis stock is volatile — it swings about 3% on a typical day and fell roughly 61% in its worst 12-month stretch.
View RiskCELC must turn its unprofitable operations into positive earnings by FY 2027. The company remains unprofitable over the past year. Recent financial performance sits well below its industry cohort. The latest quarter beat consensus estimates slightly. Peer multiples imply a price about 55% above where it trades. The price is roughly in line with the growth we forecast. The primary pillar to improve earnings is under pressure. The thesis comparison is not yet verified. Our model puts the next-quarter miss near 43%. Peer multiples imply a price about 55% above where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. CELC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 13 analysts currently covering CELC (as of Nov 2026).
Based on 5 Wall Street analysts offering 12-month price targets for CELC in the last 4 months.
Continue this research
Compare CELC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CELC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CELC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Reiteration of stock rating supports upcoming launch.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $69.24
The last 12 months of price, then the range of analyst 12-month targets from today’s $69.24.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Advances: Submit sNDA for gedatolisib in PIK3CA mutant cohort in Q3 2026
Plans for sNDA submission align with regulatory objectives.
Convertible note offering raises dilution concerns.
Convertible notes offering impacts financial strategy.
Threatens: Launch gedatolisib commercially in Q3 2026
Stock drop despite positive results raises concerns.
Advances: Expand clinical trials for gedatolisib in first-line treatment
Positive outlook on gedatolisib expansion.
Advances: Expand clinical trials for gedatolisib in first-line treatment
Trial expansion potential supports clinical objectives.
Advances: Submit sNDA for gedatolisib in PIK3CA mutant cohort in Q3 2026
FDA decision timeline aligns with regulatory goals.